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Abstract
Background: Cryopyrin-associated periodic syndrome (CAPS) is a rare disease. Knowledge on the quality of life (QoL)
and the disease’s societal impact is limited. Canakinumab is used in increasing frequency for the treatment of CAPS.
Methods: Observational study in Dutch CAPS patients. Patients completed questionnaires regarding treatment with
canakinumab at baseline and retrospectively. Quality of life was assessed using the EQ-5D-5L in adults and CHQ-PF50
in children. Impact on work and school was assessed. Caregivers' quality of life was assessed using the CarerQol.
Results: Mean quality of life scores during treatment with canakinumab were 0.769 (EQ-5D-5L), 51.1 (CHQ-P) and 57–1
(CHQ-M). Most patients experienced problems on the pain/discomfort dimension. Higher disease activity and the presence
of complications negatively influenced QoL. Half of the patients with a paid job reported absenteeism from work due to
CAPS, for an average of 8.7 days in a 4-week period. All schoolgoing patients (N= 5) reported absence from school due to
CAPS, for an average of 2.9 days. Caregivers reported gaining a lot fulfillment from providing care for their family members.
Conclusion: QoL during treatment is lower than in the general Dutch population. CAPS leads to productivity loss and
absenteeism from school, and impacts the quality of life in informal caregivers.
Keywords: Cryopyrin-associated periodic syndrome, Muckle Wells syndrome, Neonatal onset multisystem inflammatory
disease, Chronic infantile neurologic cutaneous and arthritis syndrome, Canakinumab, Anakinra, Quality of life, Societal
impact
Background
The cryopyrin-associated periodic syndrome (CAPS) is
an ultra-orphan disease [1, 2]. It is one of the classic
monogenic autoinflammatory diseases and forms a
spectrum of disease with various phenotypes, character-
ized by recurrent or continuous inflammation associated
with fever, arthralgia or arthritis, skin rash, neurologic
abnormalities, and many other symptoms [3]. CAPS is
caused by autosomal dominant mutations in the gene
encoding the nucleotide-binding oligomerization domain,
leucin-rich repeat and pyrin domain containing 3 protein
(NLRP3). This protein forms the cornerstone of the
NLRP3-inflammasome, a protein complex involved in
the innate immune system. Activation of the NLRP3-
inflammasome leads to overproduction and activation of
the pro-inflammatory cytokine interleukin-1 beta (IL-1β)
[3]. Because of this, IL-1 inhibition with anakinra or cana-
kinumab is the most effective treatment for CAPS [4].
Efficacy and side effects for canakinumab and anakinra
are comparable [5]. Treatment with canakinumab is over
ten times as expensive as treatment with anakinra [6].
The primary aim of the current study is to quantify
quality of life in patients with CAPS. Secondary aim was
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assessment of the broader societal impact of CAPS on
patient’s work and school.
Methods
Patient population
All patients with a clinical diagnosis of CAPS in the
Netherlands were eligible to participate in the study. In
2011, canakinumab was given an orphan designation for
the treatment of CAPS in the Netherlands. Conse-
quently, canakinumab could only be prescribed in two
tertiary referral centers: the Radboud university medical
center (Radboudumc, Nijmegen, the Netherlands) and
the Erasmus medical center (Erasmus MC, Rotterdam,
the Netherlands). As a result of this rule, all CAPS pa-
tients currently using or ever having used canakinumab
were regularly evaluated in these hospitals. Since 2016,
canakinumab can also be prescribed in other centers.
Patients that had not been treated in the Radboudumc
or Erasmus MC were identified through personal
communication with consultants in other Dutch tertiary
referral centers.
This study was assessed by the local medical ethics com-
mittees of the Radboudumc (registration number 2015–
1643), Erasmus MC (registration number 2015–501), and
university medical center Groningen (registration number
2015/166) and according to Dutch law was exempt from
approval by all three, because of its retrospective and ob-
servational design and the anonymous storage of patient
data. All patients or their parents gave written informed
consent to participate in this study.
Instruments
Quality of life in CAPS patients
Quality of life in patients above the age of 12 was
assessed using the Euroqol EQ-5D-5L instrument [7].
Quality of life was expressed in utilities. A utility is an
index value of health, commonly standardized between 1
(perfect health) and 0 (dead). Utilities are not disease-
specific, allowing comparison between different diseases
and health care interventions. Dutch tariffs were used to
derive utilities from the EQ-5D-5L. EQ-5D-5L utilities
range from − 0.466 to 1.00 [8].
For children < 18 years the Child Health Questionnaire,
Parent Form 50 (CHQ-PF50) [9] was completed by the
patient’s parents. Although this questionnaire is not vali-
dated for children less than 5 years of age, it was used any-
way as no alternative validated questionnaires for quality
of life are available for this age group. Patients between
the ages of 12 and 18 years or their parents completed
both the CHQ-PF50 and EQ-5D-5L questionnaires. The
CHQ-PF50 can be transformed into two summary
measures: physical and psychosocial functioning, for
which a score of 50 represents the average norm-
based score in the US population [10].
Quality of life in caregivers
Quality of life of informal caregivers was assessed using
the CarerQol instrument [11]. An overall quality of life
score can be derived using a Dutch tariff (i.e. a set of re-
gression coefficients derived from a valuation study),
which transforms quality of life to a scale from zero
(worst situation) to 100 (best situation) [12].
Impact on school and work
For patients that went to school, impact of CAPS on
school was assessed measuring the number of days ab-
sent from school. For patients with a job, CAPS’ impact
on work was assessed using the iMTA productivity cost
questionnaire (iPCQ) [13].
CAPS symptoms
Epidemiologic data and data on CAPS phenotype were
collected from the medical record by one of the investi-
gators. CAPS disease activity was prospectively measured
upon entering the study using the Auto-Inflammatory
Disease Activity Index (AIDAI) questionnaire [14]. The
corresponding total AIDAI score ranges from zero to 13
points per day, with higher scores indicating more severe
disease activity. This questionnaire was filled out during
two consecutive months. As an alternative, a modified
version of AIDAI via an online questionnaire was made
available, in which all criteria from the conventional
AIDAI were scored on a monthly basis during 12 con-
secutive months. Patients were free to choose between
using the conventional or online AIDAI. Patients using
the online version received a monthly email reminder
containing a link to the questionnaire.
Data collection
Data were collected between April 2015 and April 2017.
For each individual patient, total study duration was 1 year,
during which patients were asked to complete all ques-
tionnaires on quality of life and production loss described
above two times: at baseline (T = 0), and a second time,
looking back on the time before they used canakinumab.
All questionnaires, with exception of the online AIDAI,
were sent by mail and included a detailed instruction
letter and pre-paid return envelope. If patients did not re-
turn their questionnaires within 2 months, they received a
reminder via telephone, post, or email.
Data analysis
Analyses were performed in Stata, version 14.1 (Stata-
Corp, 2015). Due to the limited number of patients in
the sample, no statistical tests were performed.
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Results
CAPS population
A total of 40 CAPS patients were identified during the
study, of which 31 were adults (77.5%), five adolescents
aged 12 to 18 years (12.5%), and four children younger
than 12 years (10.0%). Twenty patients (50%) were male.
The total prevalence of CAPS in The Netherlands is 1 in
435.000 inhabitants. Twenty-four of the 40 CAPS patients
(60.0%) were included in the study. The main reason for
exclusion was the absence of informed consent (12
patients, 30.0%). One patient was excluded because of a
language barrier, and another patient was lost to follow up.
Two additional patients were not included as they came to
the attention of the investigators after the inclusion period
of the study had been closed. Median age at the start of the
study was 28.5 years (range 5–82 years). Over 50% of
patients had CAPS-related complications (Table 1).
Out of the 24 patients included in the study, 17 com-
pleted the quality of life questionnaires and could be
included in the analysis: three children, two adolescents,
and 12 adults. There were no significant differences be-
tween the entire Dutch CAPS population and the study
population (Additional file 1).
Quality of life in CAPS patients during treatment with
canakinumab
At the start of the study, the average EQ-5D-5L quality
of life for adults and adolescents receiving canakinumab
(N = 14) was 0.769 (SD = 0.178).(Table 2) One female pa-
tients had a utility value of 1.000, indicating perfect
health despite her disease. The minimum EQ-5D score
was 0.296, observed in one male patient. None of the pa-
tients reported to have extreme problems on any of the
dimensions of the EQ-5D. For both self-care and anx-
iety/depression, 86% of patients reported no problems.
Patients reported most problems on the pain/discom-
fort dimension, for which 86% of patients reported to
have a problem. (Fig. 1).
For five paediatric patients data on quality of life dur-
ing treatment with canakinumab were available at T = 0
(Table 2). The average score on CHQ-physical (51.1) and
CHQ-psychosocial (57.1) were close to the standardized
score of 50 in the general US population. Variation in
CHQ scores between patients was limited (range CHQ-
physical 46.9–58.7, range CHQ-psychosocial: 54.3–61.7).
Quality of life during treatment with anakinra
Eight patients completed the questionnaire recalling
their experiences during treatment with anakinra. In all
these patients, anakinra had been stopped when canaki-
numab was started, and the median time between the
stop of anakinra and the questionnaire was 49.5 months
(range 1–76 months). At T = 0, three patients reported
higher quality of life during canakinumab treatment,
while two patients reported higher quality of life during
treatment with anakinra. Three patients reported no dif-
ferences in quality of life during both treatments. On
average, quality of life was higher during treatment with
canakinumab than during treatment with anakinra, with
an average difference of 0.110 between the two treat-
ments. Variation in quality of life differences was sub-
stantial (SD = 0.269).
Quality of life and disease activity
Quality of life values were negatively correlated to
AIDAI scores (r = − 0.572, n = 8); patients with higher
disease activity had lower quality of life scores. (Table 2).
Patients with CAPS-related complications had lower
quality of life than patients without complications (0.
720 ± 0.184 versus 0.890 ± 0.078 at T = 0).
Impact of CAPS on school and work
A total of five patients were attending school: three went
to primary school, one to secondary school, and one to
higher education. All of these patients had called in sick
at least 1 day (average 2.9 days) in a 4-week period.
Six of the adult patients had a paid job or were self-
employed, two patients were retired and one patients
had been declared unfit for work. Three of the six pa-
tients with a paid job reported they had been absent
from work in a 4 week period, with an average of 8.
7 days. Three patients were less productive at work and
three patients were unable to perform all their unpaid
work activities (such as household or volunteer work).
Caregivers’ quality of life
Six caregivers were included in the study. Five were
the patient’s partner and one was the patient’s
mother. On average, these caregivers provided 9 hours
of caregiving per week, particularly related to house-
hold activities and social interaction. Of all caregivers,
83% derived a lot of fulfillment from providing infor-
mal care. None of the caregivers reported severe
problems on any of the domains of the CarerQol.
Three (50.0%) reported mental health problems re-
lated to their caregiving. The average CarerQol score
was 87.8 (SD = 12.7) and the minimum score was 64.
4. One caregiver reported the maximum quality of life
score of 100. CarerQol score was strongly and posi-
tively correlated with the patient’s quality of life (r =
0.666).
Discussion
This questionnaire-based study assessed health related
quality of life of patients with CAPS, most of whom had
been treated with canakinumab. Median treatment dur-
ation was four years. The average quality of life was 0.769,
which is lower than the average utility value for the
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general Dutch population (corrected for gender: 0.87) [8].
CAPS-related complications and higher disease activity
negatively influence quality of life. Absenteeism from
school or work is frequent in patients with CAPS.
The current study is the first to report utility values
for patients with CAPS, and therefore direct comparison
to other studies is impossible. In children with CAPS,
the Physical CHQ scores found in our study were similar
to those from a previous study in CAPS patients treated
with canakinumab [15]. The average psychosocial CHQ
score was higher in our study, but it should be noted that
the CHQ was only available for five patients. The impact
of CAPS on quality of life lies between that of patients
with rheumatoid arthritis (average EQ-5D-5 L utility value
0.43–0.75) and type 1 diabetes mellitus (average EQ-5D-
5 L utility value 0.88) in the Netherlands [16, 17].
A phase III study showed that quality of life in
CAPS patients approached values of the general
population after 8 days, 8 and 48 weeks of treatment
with canakinumab [18]. Another study assessed the
quality of life in predominantly paediatric CAPS pa-
tients, and showed that patients who received canaki-
numab had quality of life scores similar to healthy
controls after 12 weeks of treatment [15]. In our
study we found that quality of life was less in CAPS
patients than in the general population. The longer
treatment duration in our study compared to the
other studies, the fact that the other two were clinical
research studies, in which more intensive disease ac-
tivity monitoring may lead to improvements in dis-
ease control and consequently quality of life, or the
use of different questionnaires may explain the differ-
ent results.
Eight patients completed a retrospective questionnaire
recalling their quality of life during treatment with ana-
kinra, with a median interval between the stop of ana-
kinra and the questionnaire of 49.5 months. Their
average EQ-5D value during anakinra treatment was 0.
756, which is similar to the overall population. When
compared to treatment with anakinra, quality of life on
average was higher during treatment with canakinumab.
The current results comparing quality of life between
treatment with anakinra and canakinumab may be influ-
enced by the retrospective nature of the questionnaire
used, which may induce recall bias, and the small
Table 1 Patient characteristics and prevalence of CAPS
symptoms
Included in study
Number of patients 24
Male gender 9 (37.5%)
Age group
Child (0–12 years) 4 (16.7%)
Adolescent (12–18 years) 3 (12.5%)
Adult (18 years or older) 17 (70.8%)
Age (years, median (range))
Onset 5 (0–54)
Diagnosis 20 (1–76)
Start anti-IL-1 19 (1–76)
Start study 28 (5–82)
T0 treatment
No 2 (8.3%)
Anakinra 3 (12.5%)
Canakinumab 19 (79.2%)
Duration of treatment at T0 (months, median (range))
Anakinra 46 (42–48)
Canakinumab 49 (1–76)
Dose (mg, median (range)))
Anakinra 100
Canakinumab 150 (45–300)
Dose interval (median, (range))
Anakinra (days) 1
Canakinumab (weeks) 8 (4–10)
Pattern
Continuous 5 (20.8%)
Episodic 10 (41.7%)
Continuous with flares 9 (37.5%)
NLRP3 mutation
V198 M 5 (20.8%)
T348 M 3 (12.5%)
Y859H 3 (12.5%)
W414 L 3 (12.5%)
A439V 2 (8.3%)
R488K 1 (4.2%)
No mutation 7 (29.2%)
Symptoms
Fever 13 (54.2%)
Skin rash 20 (83.3%)
Musculoskeletal complaints 21 (87.5%)
Ocular symptoms 13 (54.2%)
Neurologic symptoms 16 (66.7%)
Gastrointestinal symptoms 8 (33.3%)
Table 1 Patient characteristics and prevalence of CAPS
symptoms (Continued)
Included in study
Lymphoreticular symptoms 4 (16.7%)
Cardiopulmonal symptoms 3 (12.5%)
Other symptoms 8 (33.3%)
Complications 13 (54.2%)
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number of patients reporting their experiences with ana-
kinra. However, as almost all patients in the Netherlands
are currently on canakinumab, it was not possible to
prospectively compare quality of life between treatment
with anakinra and canakinumab.
There are no other studies directly comparing QoL in
CAPS patients treated with anakinra or canakinumab.
Kuemmerle-Deschner et al. compared the effectiveness
of treatment with anakinra and canakinumab in patients
with CAPS [5]. Of the 12 patients treated with anakinra,
75% had clinical and biochemical remission after a me-
dian follow up of 50 months, while 93% of the 14 CAPS
patients treated with canakinumab showed remission
after a median follow up of 52 months. As this study
shows that canakinumab is possibly more effective than
anakinra in patients with CAPS, this could explain the
higher quality of life during canakinumab treatment.
Quality of life was not assessed in this study.
In a quality of life study including 13 paediatric CAPS
patients treated with anakinra, both the physical sum-
mary score and the psychosocial summary score for the
CHQ-PF50 increased significantly during a median fol-
low up of 37.5 months and showed normalization of
most physical activities. On the physiological domains,
patients scored less beneficial on parental impact time
and family activities [19]. This could be explained by the
fact that treatment with anakinra requires daily subcuta-
neous injections, which, in case of children, must be ad-
ministered by the caregiver, where canakinumab is given
once every 4 to 8 weeks or even less frequently.
Although treatment with IL-1 blocking agents may be
highly effective [5], patients with CAPS are often absent
Table 2 Quality of life in 24 CAPS patients at baseline
Patient Age (years) Gender Disease duration
to start T0 drug
(years)
Druga Treatment duration
(months)
EQ-5D CHQ-physicalb CHQ-psycho socialb AIDAI
1001 62.6 M 26.3 Cana 150q6w 51 0.296 9.7
1002 39.0 M UK Cana 150q6w 51 0.786
1003 59.2 F 38.8 Cana 150q8w 16 0.848 4.2
1004 59.2 F 0.33 Cana 150 q8w 57
1005 34.7 F No
1006 28.9 F UK Cana 150q8w 1 0.680
1007 61.2 F UK Cana 150q8w 10 0.813
1008 65.0 M UK Cana 150q8w 76 0.533 0.0
1009 69.1 M UK Cana 150q8w 55 0.852
2001 24.6 M 20.25 Cana 150q8w 51 0.887 0.1
2002 65.8 M 41.5 Cana 150q8w 51 0.695
2003 82.0 M 48.4 Ana 100q1d 42
2004 52.0 F 39.3 Cana 300q4w 56 0.848 2.8
2005 54.6 F UK Cana 150q10w 33 0.752 0.4
2006 5.6 M 4.7 Cana 100q8w 10
2007 15.5 F 11.4 Cana 150q10w 48 1.000 58.7 54.3
2008 5.3 F 2.1 Cana 45q8w 29 46.9 57.7 0.1
2009 23.0 F No
2010 8.2 F 4.1 Cana 90q8w 48 49.1 59.3 0.0
2011 8.4 F 3.0 Cana 50q8w 20 52.7 61.7 0.0
2012 16.0 M UK Ana 100q1d 48
2013 16.2 F 4.7 Cana 150q10w 49 0.887 47.9 57.1
2014 24.4 F 19.1 Cana 150q8w 57 0.887 3.4
2015 23.1 F 19.2 Ana 100q1d 46
Median 48
Mean 0.769 51.1 57.1 2.1
Ana anakinra, cana canakinumab, d day, q each, w week
aDrug doses are in mg per time interval, e.g. 150q8w = 150 mg every 8 weeks
bCHQ-PF was only performed in patients < 18 years of age
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from work or school. CAPS negatively influences care-
givers’ quality of life, and their quality of life depends on
CAPS disease activity.
A recent French study also assessed quality of life in
CAPS patients who had received at least one dose of
canakinumab, using a descriptive interview, and found
that the start of canakinumab was associated with an in-
crease in different social activities. Family relations,
friendships, and love lives were considered more fulfill-
ing in approximately 40% of patients [20]. This study
also reported that initiation of canakinumab treatment
was associated with less absenteeism from school, less
learning difficulties, or grade repetitions. Adults were
less absent from work than before canakinumab treat-
ment. Although this study shows that the start of canaki-
numab is associated with increases in different aspects
of social lives, it also shows that, even when treated with
canakinumab, CAPS keeps having an influence on qual-
ity of life and the daily life activities of patients. Results
from this study are not directly comparable to our re-
sults, as different questionnaires were used. Also, we
studied patients currently using canakinumab, where the
French study included patients that had ever received
one or more doses of canakinumab.
In our study, the CarerQol score for informal care-
givers of CAPS patients was 87.8, which is higher than
the average score of 79.1 for caregivers in the general
Dutch population [21]. Still, half of the caregivers in our
study reported mental health problems related to pro-
viding care. Only a small number of informal caregivers
were included in the study. This is due to the fact that
some of the patients do not receive informal care as they
are fully independent in their daily activities, that they
do not recognize informal care as such, or that the care-
giver does not recognize their help for the patient as
informal care. Koné-Paut et al. found that informal care-
givers of CAPS patients on average spent half an hour
per week on informal care, where we found that care-
givers provided 9 hours of care per week. This difference
could be explained by the use of different questionnaires
with different definitions of informal care, or the small
number of caregivers in our cohort. We found that care-
giving led to fulfillment for many of the caregivers. In
the French study, the start of canakinumab was associ-
ated with an increase in free time for the caregiver, and
a decrease in absenteeism from work for the caregiver
[20].
Our study has several limitations. Studies in orphan
diseases are necessarily done in small study populations.
In this study 60.0% of the total Dutch CAPS population
of 40 patients was included. International data collection
could increase sample size and may lead to more accur-
ate estimates of quality of life. However, it may be hard
to compare such data as quality of life or effects on life,
school or work between international cohorts because of
cultural differences. The observational design of this
study entails that selection bias cannot be ruled out. It
could be possible that patients participating in the study
may differ from patients that declined to participate.
There were no differences in gender or age between par-
ticipants and non-participants, but the treating physi-
cians of the patients confirm that some of the patients
that declined participation had a more severe CAPS
phenotype. Measurement of quality of life can only be
done using questionnaires, which will not encompass all
aspects influencing quality of life. We tried to overcome
this limitation as much as possible by using validated
quality of life questionnaires. Quality of life may be in-
fluenced by either the disease, its treatment, or a com-
bination of both, and which factor influences QoL the
Fig. 1 Performance of CAPS patients on the dimensions of the EQ-5D-5 L
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most cannot be derived from our study. For the retro-
spective part of this study no validated questionnaires
were available, possibly influencing the results. Also, pa-
tients had been treated with canakinumab for a median
of approximately 4 years. The long interval between the
current and the previous treatment could lead to recall
bias. Because of the observational design of the study
and the fact that only five of the 24 patients in our co-
hort did not use canakinumab, no prospective control
arm for comparison of quality of life between different
treatments was available.
With the introduction of a growing number of (expen-
sive) orphan drugs, research in rare diseases is becoming
increasingly relevant. The results from this study quan-
tify the burden of disease for patients with CAPS during
treatment with canakinumab and the implications for
their direct environment. We show that quality of life
measured with the EQ-5D-5L is an accurate way to as-
sess disease severity in CAPS, as quality of life correlated
with disease activity measured with AIDAI. The utility
values derived in this study are important input values for
future cost-effectiveness studies. For cost-effectiveness
studies, it is necessary to divide patients into multiple dis-
tinct health states for modeling. The small sample size in
orphan diseases in general and CAPS in specific may lead
to implausible quality of health values. Future results
could investigate cost-effectiveness and could include
research on cost of medication. The current study shows
that including a societal perspective is important, as CAPS
patients report that their disease has significant impact on
work, ability, school attendance, and the use of informal
care. Costs outside the health care factor, such as the costs
associated with informal care and loss of productivity,
should be taken into account.
Conclusion
Quality of life in patients with CAPS during treatment with
anti-IL-1 therapy is decreased compared to quality of life
in the general population. CAPS is associated with produc-
tion losses in adult patients and absenteeism from school
in children. Informal caregivers of patients with CAPS have
higher care-related quality of life than other Dutch infor-
mal caregivers. Because of this, adequate disease control
and attention to the societal impact of the disease and its
treatment are pivotal in the care for patients with CAPS.
Additional file
Additional file 1 Detailed overview of CAPS symptoms and
complications in 24 Dutch CAPS patients. (DOCX 14 kb)
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